DJ
Mesoblast Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Rexlemestrocel-L (REVASCOR®) | Advanced Chronic Heart Failure with Left Ventricular Assist Device (LVAD) | Phase 3 |
| Rexlemestrocel-L | Chronic Low Back Pain due to Degenerative Disc Disease | Phase 3 |
| Remestemcel-L (RYONCIL®) | Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) in children | Phase 3 |
| Remestemcel-L | Acute Respiratory Distress Syndrome (ARDS) | Phase 2/3 |
| MPC-06-ID | Inflammatory Bowel Disease (Crohn's Fistula) | Phase 2 |
| MPC-300-IV | Biologic-Refractory Rheumatoid Arthritis | Phase 2 |
Leadership Team at Mesoblast
DS
Dr. Silviu Itescu
Founder, Chief Executive Officer, and Executive Director
JM
Josh Muntner
Chief Financial Officer
DF
Dr. Fred Grossman
Chief Medical Officer
DD
Dr. Donna Skerrett
Chief Executive Officer, Mesoblast Inc. (USA)
ER
Eric Rose, M.D.
Chairman of the Board
DA
Dr. Andrew J. Perlman
Independent Non-Executive Director
DE
Dr. Elizabeth (Liz) G. Nabel
Independent Non-Executive Director
DB
Dr. Bassem I. Razzouk
Independent Non-Executive Director
DJ
Dr. Julie G. Parsonnet
Independent Non-Executive Director
DA
Dr. Adrian (Adi) G. K. (Koh)
Independent Non-Executive Director